Purpose of Review
We reviewed the HIV and opioid literature relevant to harm reduction strategies for those with criminal justice experience.
Opioid use in the United States has risen at an alarming rate recently. This has led to increased numbers of people who inject drugs, placing new populations at risk for HIV, including those who have criminal justice experience. In recent years, there has been a gradual decrease in the number of individuals under the supervision of the criminal justice system. However, concurrently, there has been a rise in the number of individuals incarcerated in jails in rural counties that are at the center of the current opioid epidemic.
We provide a number of harm reduction strategies that could be implemented in correctional settings such as access and linkage to medication-assisted treatment, connection to syringe exchange programs and safe injection facilities (where available), and the repackaging of pre-exposure prophylaxis as a harm reduction tool.
This is a preview of subscription content,to check access.
Access this article
Kaeble D, Glaze L. Correctional populations in the United States, 2015. Washington, DC: Bureau of Justice Statistics; 2016.
Kang-Brown J, Subramanian R. Out of sight: The growth of rural jails in America. New York, NY: Vera Institute of Justice; 2017.
Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States and Dependent Areas, 2015. HIV Surveillance Report (27).
Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users—United States, 2002–2013. MMWR. 2015;64(26):719–25.
Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releases from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. Plos One. 2009;4:e7558.
Mumola CJ, Karberg JC. Drug use and dependence, state and federal prisoners, 2004. Washington, DC: Bureau of Justice Statistics; 2006.
Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison—a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.
Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(5):592–600.
Ramaswamy M, Freudenberg N. Sex partnerships, health, and social risks of young men leaving jail: analyzing data from a randomized controlled trial. BMC Public Health. 2010;10(1):689–97. PMCID: PMC2988744
Milloy MJ, Buxton J, Wood E, Li K, Julio SG, Kerr T. Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis. BMC Public Health. 2009;9:156.
Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53(7):725–31.
Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215–21.
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med. 2014;174(5):721–9.
Iroh PA, Mayo H, Nijhawan AE. The HIV care Cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health. 2015;105:e5–e16.
Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). J Correct Health Care. 2015;21(1):12–26.
Texas Christian University Institute of Behavioral Research. TCU drug screen 5 opioid supplement. Fort Worth, TX: TCU; 2017.
Perry AE, Neilson M, Martyn-St James M, Glanville JM, Woodhouse R, Godfrey C, Hewitt C. Pharmacological interventions for drug-using offenders. Cochrane Database Syst Rev 2015, Issue 6. Art. No.: CD010862.
McKenzie M, Zaller N, Dickman SL, Green TC, Parihk A, Friedmann PD, et al. A randomized trial of methadone initiation prior to release from incarceration. Subst Abuse. 2012;33:19–29.
Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103:1333–42.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007;91:220–7.
Brinkley-Rubinstein L, McKenzie M, Macmadu A, Zaller N, Larney S, Dauria E, Rich J. A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: findings at 12-months post-release. Drug Alcohol Depend. 2018.
Green TC, Clarke J, Brinkley-Rubinstein L, Marshall BD, Alexander-Scott N, Boss R, Rich JD. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiat. 2018;75(4):405–7.
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend. 2017;174:158–70.
Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, et al. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction. 2017;112(6):1036–44.
Nosyk B, Min JE, Colley G, Lima VD, Yip B, Milloy MJS, et al. The causal effect of opioid substitution treatment on HAART medication refill adherence. AIDS. 2015;29(8):965–73.
Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. Am J Drug Alcohol Abuse. 2011;37(1):12–21.
Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22–32.
Springer S, Barbour R, Azar M, Alice FL, Di Paola A. Results of a double blind placebo controlled randomized trial of extended-release naltrexone among HIV+ inmates with alcohol use disorders. The College on Problems of Drug Dependence; 2017 June 17–22; Montréal, Canada; 2017.
Springer S, Barbour R, Azar M, et al. Results of a double blind placebo-controlled randomized trial of extended-release naltrexone among HIV+ inmates with opioid dependence The College on Problems of Drug Dependence; 2017 June 17–22; Montréal, Canada; 2017.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.
Centers for Disease Control and Prevention (CDC). Pre-exposure prophylaxis for the prevention of HIV infection in the United States-2014: A clinical practice guideline. Atlanta, GA: CDC; 2014.
Brinkley-Rubinstein L, Dauria E, Tolou-Shams M, Christopoulos K, Chan PA, Beckwith CG, et al. The path to implementation of HIV pre-exposure prophylaxis for people involved in criminal justice systems. Curr. HIV/AIDS Rep. 2018;15(2):93–5.
Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Doing harm reduction better: syringe exchange in the United States. Addiction. 2009;104:1441–6.
Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in over- dose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429–37.
Kerr T, Small W, Moore D, Wood E. A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver’s safer injection facility. Int J Drug Policy. 2007;18(1):37–45.
Milloy MJ, Kerr T, Mathias R, Zhang R, Montaner JS, Tyndall M, et al. Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. Am J Drug Alcohol Abuse. 2008;34(4):499–509.
Wood E, Tyndall MW, Lai C, Montaner JS, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy. 2006;1:13.
Kerr T, Stoltz JA, Tyndall M, Li K, Zhang R, Montaner J, et al. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ. 2006;332(7535):220–2.
Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, et al. Rationale for evaluating North America’s first medically supervised safer- injecting facility. Lancet Infect Dis. 2004;4(5):301–6.
Wood E, Tyndall MW, Zhang R, Montaner JS, Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction. 2007;102(6):916–9. https://doi.org/10.1111/j.1360-0443.2007.01818.x.
DeBeck K, Kerr T, Bird L, Zhang R, Marsh D, Tyndall M, et al. Injection drug use cessation and use of North America’s first medically supervised safer injecting facility. Drug Alcohol Depend. 2011;113(2–3):172–6.
Kimber J, Dolan K, van Beek I, Hedrich D, Zurhold H. Drug consumption facilities: an update since 2000. Drug Alcohol Rev. 2003;22(2):227–33.
Conflict of Interest
The authors declare that they have no competing interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
This article is part of the Topical Collection on The Global Epidemic
About this article
Cite this article
Brinkley-Rubinstein, L., Cloud, D., Drucker, E. et al. Opioid Use Among Those Who Have Criminal Justice Experience: Harm Reduction Strategies to Lessen HIV Risk. Curr HIV/AIDS Rep 15, 255–258 (2018). https://doi.org/10.1007/s11904-018-0394-z